The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
Open accessAbstract
Plasma protein binding can be an effective means of improving the pharmacokinetic properties of otherwise short lived molecules. Using peptide phage display, we identified a series of peptides having the core sequence DICLPRWGCLW that specifically bind serum albumin from multiple species with high affinity. These peptides bind to albumin with 1:1 stoichiometry at a site distinct from known small molecule binding sites. Using surface plasmon resonance, the dissociation equilibrium constant of peptide SA21 (Ac-RLIEDICLPRWGCLWEDD-NH(2)) was determined to be 266 +/- 8, 320 +/- 22, and 467 +/- 47 nm for rat, rabbit, and human albumin, respectively. SA21 has an unusually long half-life of 2.3 h when injected by intravenous bolus into rabbits. A related sequence, fused to the anti-tissue factor Fab of D3H44 (Presta, L., Sims, P., Meng, Y. G., Moran, P., Bullens, S., Bunting, S., Schoenfeld, J., Lowe, D., Lai, J., Rancatore, P., Iverson, M., Lim, A., Chisholm, V., Kelley, R. F., Riederer, M., and Kirchhofer, D. (2001) Thromb. Haemost. 85, 379-389), enabled the Fab to bind albumin with similar affinity to that of SA21 while retaining the ability of the Fab to bind tissue factor. This interaction with albumin resulted in reduced in vivo clearance of 25- and 58-fold in mice and rabbits, respectively, when compared with the wild-type D3H44 Fab. The half-life was extended 37-fold to 32.4 h in rabbits and 26-fold to 10.4 h in mice, achieving 25-43% of the albumin half-life in these animals. These half-lives exceed those of a Fab'(2) and are comparable with those seen for polyethylene glycol-conjugated Fab molecules, immunoadhesins, and albumin fusions, suggesting a novel and generic method for improving the pharmacokinetic properties of rapidly cleared proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[19] Rapid and efficient site-specific mutagenesis without phenotypic selection
Kunkel, T. A., Roberts, J. D., & Zakour, R. A. (1987) · Methods in Enzymology · doi:10.1016/0076-6879(87)54085-x · Cited by 5,261
Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926
Clinical pharmacokinetics; concepts and applications
(1989) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(89)90348-0 · Cited by 2,223
Peters, T. (1985) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60065-0 · Cited by 2,181
Removal of endotoxin from protein solutions by phase separation using triton X-114
Aida, Y., & Pabst, M. J. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90029-u · Cited by 597
Delivery of Novel Therapeutic Agents in Tumors: Physiological Barriers and Strategies
Jain, R. K. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/81.8.570 · Cited by 557
Kurtzhals, P., Havelund, S., Jonassen, I., Kiehr, B., Larsen, U. D., Ribel, U., & Markussen, J. (1995) · Biochemical Journal · doi:10.1042/bj3120725 · Cited by 334
Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol
Clark, R., Olson, K., Fuh, G., Marian, M., Mortensen, D., Teshima, G., Chang, S., Chu, H., Mukku, V., Canova-Davis, E., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.36.21969 · Cited by 246
Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs
Markussen, J., Havelund, S., Kurtzhals, P., Andersen, A. S., Halstr�m, J., Hasselager, E., Larsen, U. D., Ribel, U., Sch�ffer, L., Vad, K., et al. (1996) · Diabetologia · doi:10.1007/bf00418343 · Cited by 233
Affinity Maturation of Human Growth Hormone by Monovalent Phage Display
Lowman, H. B., & Wells, J. A. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1612 · Cited by 228
Cited by
Human serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Antimicrobial peptides: key components of the innate immune system
Pasupuleti, M., Schmidtchen, A., & Malmsten, M. (2012) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2011.594423 · Cited by 799
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Unraveling the mysteries of serum albumin—more than just a serum protein
Merlot, A. M., Kalinowski, D. S., & Richardson, D. R. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00299 · Cited by 641
Albumin as a versatile platform for drug half-life extension
Sleep, D., Cameron, J., & Evans, L. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.023 · Cited by 485
Albumin and its application in drug delivery
Sleep, D. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.993313 · Cited by 464
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 386
Domain antibodies: proteins for therapy
Holt, L. J., Herring, C., Jespers, L. S., Woolven, B. P., & Tomlinson, I. M. (2003) · Trends in Biotechnology · doi:10.1016/j.tibtech.2003.08.007 · Cited by 345
Discovering and improving novel peptide therapeutics
MCGREGOR, D. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.002 · Cited by 331
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 305
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Coppieters, K., Dreier, T., Silence, K., Haard, H. D., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., Wiele, C. V. D., Staelens, L., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21827 · Cited by 303
Phage display-derived peptides as therapeutic alternatives to antibodies
Ladner, R. C., Sato, A. K., Gorzelany, J., & de Souza, M. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03104-6 · Cited by 301
Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis
Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., Van Huysse, J., Demetter, P., Steidler, L., Remaut, E., et al. (2010) · Mucosal Immunology · doi:10.1038/mi.2009.116 · Cited by 289
An Eighteen‐Membered Macrocyclic Ligand for Actinium‐225 Targeted Alpha Therapy
Thiele, N. A., Brown, V., Kelly, J. M., Amor‐Coarasa, A., Jermilova, U., MacMillan, S. N., Nikolopoulou, A., Ponnala, S., Ramogida, C. F., Robertson, A. K. H., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201709532 · Cited by 288
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & van Bergen en Henegouwen, P. M. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26145 · Cited by 284
Efficient Selection of DARPins with Sub-nanomolar Affinities using SRP Phage Display
Steiner, D., Forrer, P., & Plückthun, A. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.07.085 · Cited by 271
The protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
Applications of single-chain variable fragment antibodies in therapeutics and diagnostics
Weisser, N. E., & Hall, J. C. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.04.004 · Cited by 261
Nanobodies as novel agents for cancer therapy
Revets, H., De Baetselier, P., & Muyldermans, S. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.111 · Cited by 254
Lien, S., & Lowman, H. B. (2003) · Trends in Biotechnology · doi:10.1016/j.tibtech.2003.10.005 · Cited by 209
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707678 · Cited by 182
“In the absence of such a domain, the half-life of the VNAs used here is substantially extended by the attached albuminbinding peptide (Dennis et al, 2002) and have a half-life of about 1 day in mice (Mukherjee et al, 2014), significantly shorter than the half-life typical for mAbs.”
BackgroundZorzi, A., Middendorp, S. J., Wilbs, J., Deyle, K., & Heinis, C. (2017) · Nature Communications · doi:10.1038/ncomms16092 · Cited by 141
“4b, Supplementary Figs 11 and 13).”
InfluentialNessler, I., Khera, E., Vance, S., Kopp, A., Qiu, Q., Keating, T. A., Abu-Yousif, A. O., Sandal, T., Legg, J., Thompson, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2295 · Cited by 128
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery
Rojas, L. A., Condezo, G. N., Moreno, R., Fajardo, C. A., Arias-Badia, M., San Martín, C., & Alemany, R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.004 · Cited by 66
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114538 · Cited by 57
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
Metadata
- Authors
- Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., & Damico, L. A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 277
- Issue
- 38
- Pages
- 35035-35043
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2168848424
- Cited by
- 508
- References
- 24
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.